How to Select and Monitor Brexanolone for Postpartum Depression
How should clinicians identify appropriate candidates for brexanolone infusion and monitor them during treatment for postpartum depression?
Women with moderate-to-severe postpartum depression may improve rapidly during brexanolone treatment, but the inpatient infusion requires structured eligibility screening and close monitoring. This guide applies to the inpatient-style workflow described in the study and helps clinicians align patient selection, dosing, and observation with the protocol actually used.
-
Confirm postpartum depression severity and timing
Identify women 18 to 45 years old who are within 8 months postpartum and meet DSM-5 criteria for major depressive disorder with peripartum onset. In the study, participants also had a baseline 17-item Hamilton Depression Rating Scale score of 21 or higher, representing moderate-to-severe illness.
-
Screen for psychiatric and medical exclusions
Exclude patients with current psychosis or mania, a history of schizophrenia, schizoaffective disorder, or bipolar disorder, a suicide attempt during the current depressive episode, or concurrent substance use disorder by self-report or drug screening. Also exclude those who received electroconvulsive therapy during the current episode, had prior brexanolone exposure, or participated in another investigational medication or device study within 30 days.
-
Verify medical readiness before infusion
Use physical examination, laboratory testing, and a 12-lead electrocardiogram to confirm that the patient is medically healthy with no clinically significant findings as determined by the treating physician. Require a negative pregnancy test before brexanolone administration and documented contraception throughout follow-up.
-
Stabilize concomitant psychotropics
Maintain psychotropic medications at a stable dose for at least 14 days before enrollment. During hospitalization for brexanolone administration, discontinue as-needed benzodiazepines, as was done in the study.
-
Administer the 60-hour infusion regimen
Deliver brexanolone using the FDA-approved 60-hour schedule: 30 µg/kg/hour during Hours 0 to 4, 60 µg/kg/hour during Hours 4 to 24, 90 µg/kg/hour during Hours 24 to 52, 60 µg/kg/hour during Hours 52 to 56, and 30 µg/kg/hour during Hours 56 to 60. The study used a programmable peristaltic infusion pump to ensure accurate delivery.
-
Follow REMS-style safety monitoring during treatment
Monitor patients throughout treatment using safety procedures consistent with the brexanolone Risk Evaluation and Mitigation Strategy protocol. Continue adverse-event surveillance during treatment and follow-up; in this study, adverse events were mild and included warm flushing, transient dizziness, headache, and venipuncture-site discomfort or bruising.
-
Assess response and remission on a defined schedule
Rate symptoms at baseline, repeatedly during the infusion, 12 hours after infusion completion, and again at 30 days, mirroring the study's 13 standardized timepoints. Define response as a 50% or greater decrease in baseline total HAMD score and remission as a total HAMD score below 7.
-
Set expectations for early improvement
Expect that substantial clinical change may emerge in the first 24 to 48 hours rather than only after the highest dose is reached. In this study, 60% achieved response by H24, 80% achieved remission by H48, all responded by H72, and remission was sustained at D30 in all 9 subjects who remitted during treatment.
Clinical Considerations
- This was a small, single-arm, open-label pilot study in 10 inpatients, so the workflow reflects a descriptive research protocol rather than a validated comparative treatment algorithm.
- Generalizability is limited because the sample consisted of Caucasian, non-Hispanic, married women treated in an inpatient setting with frequent contact from study personnel.
- Participants continued concurrent psychotropic medications, so the study cannot isolate brexanolone's independent contribution to symptom change.
- The article notes that brexanolone is no longer commercially available and that the practical treatment landscape has shifted toward zuranolone.
Bottom Line
When using the study's inpatient brexanolone protocol, screen carefully for eligibility and monitor closely during the first 24 to 48 hours because response and remission often occurred rapidly during that window.
